Updated:
Sunovion Pharmaceuticals Inc.
Improving health of people everywhere - innovative treatments, science, and tech to address patient needs in oncology, urology, women's health, rare...
Sunovion Pharmaceuticals Inc.
Improving health of people everywhere - innovative treatments, science, and tech to address patient needs in oncology, urology, women's health, rare diseases, CNS, and cell & gene therapy.
General information
Firm type
other
Location
Region
North America
Country
United States
City
Marlborough
Corporate office
Marlborough, MA, United States
Sector focus
Frequently asked questions
Who owns Sunovion Pharmaceuticals Inc.?
Sunovion is owned by Sumitomo Pharma Co., Ltd., a publicly traded Japanese pharmaceutical company listed on the Tokyo Stock Exchange. Sumitomo Pharma is part of the larger Sumitomo Chemical Group (per Sumitomo Pharma corporate filings).
What therapeutic areas does Sunovion focus on?
Sunovion's stated focus areas include oncology, women's health, urology, rare diseases, central nervous system (CNS) disorders, and cell & gene therapies (per the firm's website).
Does Sunovion disclose its financials or revenue?
Sunovion's financial data is not publicly disclosed as a standalone entity. Financial information for the parent company, Sumitomo Pharma Co., Ltd., is available in its annual reports filed in Japan.
Where is Sunovion headquartered?
Sunovion Pharmaceuticals Inc. is headquartered in Marlborough, Massachusetts, United States (per the firm's website).
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: